Solid Form of (-)-Ambrox Formed by a Bioconversion of Homofarnesol in the Presence of a Biocatalyst
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/EP2017/059327, filed Apr 20, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,844,412 | Solid Form of (-)-Ambrox Formed by a Bioconversion of Homofarnesol in the Presence of a Biocatalyst In force · High confidence | Givaudan S.A. | In force | High confidence | ||
| US 11,401,541 | Solid Form of (-)-Ambrox Formed by a Bioconversion of Homofarnesol in the Presence of a Biocatalyst In force · High confidence | Givaudan S.A. | In force | High confidence | ||
| US 11,773,419 | A Solid Form of (-)-Ambrox Formed by a Bioconversion of Homofarnesol in the Presence of a Biocatalyst In force · High confidence | Givaudan S.A. | In force | High confidence | ||
| US 12,084,699 | Solid Form of (-)-Ambrox Formed by a Bioconversion of Homofarnesol in the Presence of a Biocatalyst In force · Medium confidence | Givaudan S.A. | In force | Medium confidence | ||
| Application 18/797,477 | Solid Form of (-)-Ambrox Formed by a Bioconversion of Homofarnesol in the Presence of a Biocatalyst Pending Not granted | Givaudan S.A. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Givaudan S.A..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.